HMHamish Miller

Hamish Miller

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hamish Miller has a total of 34 co-authors. Here are the top co-authors by number of shared publications:

  • Jeremy W. Tomlinson

    Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital, Oxford, UK

    3 shared publications
  • Richard Parker

    Leeds Liver Unit St James's University Hospital Leeds UK

    3 shared publications
  • David A. Sheridan

    Institute of Translational and Stratified Medicine, University of Plymouth, Plymouth, UK

    2 shared publications
  • Pinelopi Manousou

    Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK

    2 shared publications
  • Santo Colosimo

    Department of Food, Environmental and Nutritional Sciences (DeFENS), University of Milan, 20133 Milan, Italy

    2 shared publications
  • William Alazawi

    Barts Liver Centre, Queen Mary University London and Barts Health NHS Trust, London, UK; Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK

    2 shared publications

Latest Publications

  • Glycated haemoglobin is a major predictor of disease severity in patients with NAFLD

    by Santo Colosimo, Hamish Miller, Dimitrios A. Koutoukidis, Thomas Marjot, Garry D. Tan, David J. Harman, Guruprasad P. Aithal, Pinelopi Manousou, Roberta Forlano, Richard Parker, et al.


  • Open Access

    Translating the potential of the urine steroid metabolome to stage NAFLD (TrUSt-NAFLD): study protocol for a multicentre, prospective validation study

    by Hamish Miller, David Harman, Guruprasad Padur Aithal, Pinelopi Manousou, Jeremy F Cobbold, Richard Parker, David Sheridan, Philip N Newsome, Fredrik Karpe, Matthew Neville, et al.

    Introduction Non-alcoholic fatty liver disease (NAFLD) affects approximately one in four individuals and its prevalence continues to rise. The advanced stages of NAFLD with significant liver fibrosis are associated with adverse morbidity and mortality outcomes. Currently, liver biopsy remains the ‘gold-standard’ approach to stage NAFLD severity. Although generally well tolerated, liver biopsies are associated with significant complications, are resource intensive, costly, and sample only a very small area of the liver as well as requiring day case admission to a secondary care setting. As a result, there is a significant unmet need to develop non-invasive biomarkers that can accurately stage NAFLD and limit the need for liver biopsy. The aim of this study is to validate the use of the urine steroid metabolome as a strategy to stage NAFLD severity and to compare its performance against other non-invasive NAFLD biomarkers. Methods and analysis The TrUSt-NAFLD study is a multicentre prospective test validation study aiming to recruit 310 patients with biopsy-proven and staged NAFLD across eight centres within the UK. 150 appropriately matched control patients without liver disease will be recruited through the Oxford Biobank. Blood and urine samples, alongside clinical data, will be collected from all participants. Urine samples will be analysed by liquid chromatography-tandem mass spectroscopy to quantify a panel of predefined steroid metabolites. A machine learning-based classifier, for example, Generalized Matrix Relevance Learning Vector Quantization that was trained on retrospective samples, will be applied to the prospective steroid metabolite data to determine its ability to identify those patients with advanced, as opposed to mild-moderate, liver fibrosis as a consequence of NAFLD. Ethics and dissemination Research ethical approval was granted by West Midlands, Black Country Research Ethics Committee (REC reference: 21/WM/0177). A substantial amendment (TrUSt-NAFLD-SA1) was approved on 26 November 2021. Trial registration number ISRCTN19370855.


  • Developing a risk stratification tool for advanced NAFLD fibrosis using routinely measured clinical variables in a diabetes clinic annual review

    by Hamish Miller, Santo Colosimo, Wenhao Li, Jeremy Cobbold, William Alazawi, David Harman, Guruprasad Aithal, Pinelopi Manousou, Richard Parker, Philip N Newsome, et al.